Budesonide SUN

Budesonide Sun is a medicine that was to be used to treat asthma in adults and children in whom a hand-held inhaler did not adequately control their asthma, suspected asthma in children aged 6 months to 4 years, and serious croup (a viral infection of the upper airways in children) that requires a stay in hospital.

Budesonide Sun contains the active substance budesonide, which belongs to a group of anti-inflammatory medicines known as corticosteroids. It was to be available as a suspension (250, 500 or 1,000 micrograms / 2 ml) given by inhalation through a nebuliser device.

Budesonide Sun was developed as a generic medicine. This means that Budesonide Sun was developed to contain the same active substance and work in the same way as a ‘reference medicine’ already authorised in some EU countries called Pulmicort Respules. For more information on generic medicines, see the question-and-answer document below.

Sun Pharmaceutical Industries Europe B.V. submitted Budesonide Sun to the Netherlands for a decentralised procedure. This is a procedure where one Member State (the ‘reference Member State’, in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States where the company has applied for a marketing authorisation (the ‘concerned Member States’, in this instance Germany, Italy, Poland, Spain and Sweden), as well as the United Kingdom.

However, the Member States were not able to reach an agreement and the Dutch medicines regulatory agency referred the matter to EMA for arbitration on 27 September 2019.

The grounds for the referral were concerns raised by the United Kingdom and Italy that the laboratory data submitted to support the application were not sufficient to show that Budesonide Sun is equivalent to Pulmicort Respules. In particular, the company did not demonstrate that the amount of active substance delivered by nebulisation with Budesonide Sun is equivalent to that of the reference medicine, and therefore that the medicine would have the same therapeutic effect.

Based on evaluation of the currently available data, the Agency concluded that equivalence to the reference medicinal product has not been shown. The Agency therefore concluded that the benefits of Budesonide Sun do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States.

The review of Budesonide Sun was initiated on 27 September 2019 at the request of the Netherlands, under Article 29(4) of Directive 2001/83/EC.

The review was carried out by EMA’s Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use.

A European Commission decision valid throughout the EU will be issued in due course.